Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Rating) in a research report report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Price Performance Shares of GLMD stock opened at $4.60 on Wednesday. The stock has a market capitalization of $7.73 million, a PE […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Millennium Management ,Raymond James Financial Services Advisors Inc ,Galmed Pharmaceuticals ,Institutional Trading Of Galmed Pharmaceuticals ,Galmed Pharmaceuticals Price Performance ,Galmed Pharmaceuticals Ltd ,Galmed Pharmaceuticals Company Profile ,News Ratings For Galmed Pharmaceuticals Daily ,Cambridge Investment Research Advisors Inc ,Get Rating ,James Financial Services Advisors ,Investment Research Advisors ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,